Identification of β-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer-Reference-Cited by-同舟云学术

Identification of β-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer

Published:2019-03 Issue:6 Volume:11 Page:461-470
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Chen Jian¹²³,Hou Hongwei³,Chen Huan³,Luo Yanbo³,He Yunlu³,Zhang Lirong⁴,Zhang Yunfei⁵,Liu Hansong⁶,Zhang Fangfang⁶,Liu Yong¹,Wang An¹,Hu Qingyuan³

Affiliation:

1. Institute of Applied Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, Anhui, PR China

2. Graduate school, University of Science & Technology of China, Hefei 230026, Anhui, PR China

3. Quality Safety and Framework Convention on Tobacco Control Research Team, China National Tobacco Quality Supervision & Test Center, Zhengzhou 450001, Henan, PR China

4. School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, PR China

5. Henan Cancer Hospital, Zhengzhou University, Zhengzhou 450008, Henan, PR China

6. Zhengzhou Central Hospital affiliated to Zhengzhou University, Zhengzhou 450001, Henan, PR China

Abstract

Aim: β-Hydroxybutyrate (BHB) was proved to be a differential metabolite of papillary thyroid cancer (PTC) by semiquantitative analysis, while whether BHB could be used as a potential biomarker for female PTC still needed to be validated. Materials & methods: An LC–MS/MS method with surrogate matrix was established to validate serum BHB in specified PTC patients. Conclusion: Serum BHB levels in PTCs were significantly higher than those in HCs. For both serum BHB with a cut-off value of 312.5 ng/ml and serum BHB/creatinine of 33.5 μmol/mmol, a promising prediction rate to distinguish low-grade PTCs from HCs with satisfactory sensitivity and specificity was achieved, indicating that serum BHB might be proved as a useful biomarker for low-grade female PTC.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2018-0273

Reference30 articles.

1. Thyroid cancer mortality and incidence: A global overview

2. Biologic and Clinical Perspectives on Thyroid Cancer

3. Cancer treatment and survivorship statistics, 2016

4. LC–MS/MS determination of d-mannose in human serum as a potential cancer biomarker

5. Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells;Molecules;2022-11-18

2. Melatonin alleviates insulin resistance through the PI3K/AKT signaling pathway in ovary granulosa cells of polycystic ovary syndrome;Reproductive Biology;2022-03

3. Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer;Cancers;2021-02-10

4. Alterations in plasma concentrations of energy-balance-related metabolites in patients with lung, or head & neck, cancers: Effects of radiotherapy;Journal of Proteomics;2020-02

5. Dysregulation of Ketone Body Metabolism Is Associated With Poor Prognosis for Clear Cell Renal Cell Carcinoma Patients;Frontiers in Oncology;2019-12-17